20S proteasome inhibition: designing noncovalent linear peptide mimics of the natural product TMC-95A (Q27664068)

8

object named as

Robert Huber

0 references

author name string

Nerea Gallastegui

2

0 references

Xavier Maréchal

3

0 references

Virginie Le Ravalec

4

0 references

Nicolas Basse

5

0 references

Nicolas Richy

6

0 references

Emilie Genin

7

0 references

Luis Moroder

9

0 references

Joëlle Vidal

10

0 references

Michèle Reboud-Ravaux

https://api.crossref.org/works/10.1002%2FCMDC.201000293

11

0 references

publication date

4 October 2010

0 references

published in

ChemMedChem

0 references

volume

5

0 references

issue

10

0 references

page(s)

1701-5

0 references

1 reference

7 January 2021

Molecular shredders: how proteasomes fulfill their role

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Structure of 20S proteasome from yeast at 2.4 A resolution

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

The structure of the mammalian 20S proteasome at 2.75 A resolution

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

20S proteasome and its inhibitors: crystallographic knowledge for drug development

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Novel organic proteasome inhibitors identified by virtual and in vitro screening

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

The total synthesis of proteasome inhibitors TMC-95A and TMC-95B: discovery of a new method to generate cis-propenyl amides

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Total synthesis of TMC-95A

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

A concise, total synthesis of the TMC-95A/B proteasome inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

The core structure of TMC-95A is a promising lead for reversible proteasome inhibition

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Synthesis of the Functionalized Macrocyclic Core of Proteasome Inhibitors TMC-95A and B This work was supported by grants from the National Institutes of Health (grant CA28824). We thank Dr. George Sukenick and Sylvi Rusli of the MSKCC NMR Core Faci

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Synthesis of macrocyclic peptide analogues of proteasome inhibitor TMC-95A.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

TMC-95A analogues with endocyclic biphenyl ether group as proteasome inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Linear TMC-95-based proteasome inhibitors.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Binding mode of TMC-95A analogues to eukaryotic 20S proteasome

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Synthesis of a TMC-95A ketomethylene analogue by cyclization via intramolecular Suzuki coupling

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Inhibitor-binding mode of homobelactosin C to proteasomes: new insights into class I MHC ligand generation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021

Diversity of proteasomal missions: fine tuning of the immune response

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201000293

7 January 2021